1. 171P Pharmacodynamic (PD) biomarker analysis from CheckMate (CM) 8KX: A multitumor study of a subcutaneous (SC) formulation of nivolumab (NIVO) monotherapy. (December 2022) Authors: Jackson, C.G.C.A.; Perumal, D.; Lugowska, I.; O'Donnell, A.; North, R.T.; Calvo Ferrandiz, P.A.; Latten-Jansen, L.M.; Sánchez, C.G.; Medina Rodríguez, L.M.; Santoro, A.; Li, L.; Sidik, K.; Tang, T.; Deutsch, J.S.; Taube, J.; Horak, C.; Ravimohan, S.; Lonardi, S. Journal: Immuno-oncology technology Issue: Volume 16(2022)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗